The "fact" is CTIX is not out of first in human trials for

Thought I said that, but maybe not clearly enough. Part of current valuation is future valuation. If that weren't true then the SP would not even be $1, or even 10 cents. "Ifs" are a big part of share price for all biopharma start-ups.